Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03267888 · OUTCOME

Overall Survival

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2024-09-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
From first treatment on course 1, day 1 to the earlier of date of death and/or last follow up, assessed up to 12 months

What was measured

Will be estimated using the Kaplan-Meier product-limit method.

Groups in this outcome

Radiation Therapy, Pembrolizumab

Patients undergo radiation therapy on day 1. Patients also receive pembrolizumab IV over 30 minutes on day 2 or 3. Courses with pembrolizumab repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Pembrolizumab: Given 200 mg/kg IV. Radiation Therapy: Patients will receive radiotherapy (8 Gy/1 fx) to an extra-osseous site and/or any bony site containing myeloma deposit.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Radiation Therapy, Pembrolizumab25

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Radiation Therapy, Pembrolizumab15Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        15
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    units
    Participants
description
Will be estimated using the Kaplan-Meier product-limit method.
groups
  1. description
    Patients undergo radiation therapy on day 1. Patients also receive pembrolizumab IV over 30 minutes on day 2 or 3. Courses with pembrolizumab repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Pembrolizumab: Given 200 mg/kg IV. Radiation Therapy: Patients will receive radiotherapy (8 Gy/1 fx) to an extra-osseous site and/or any bony site containing myeloma deposit.
    id
    OG000
    title
    Radiation Therapy, Pembrolizumab
param Type
NUMBER
reporting Status
POSTED
time Frame
From first treatment on course 1, day 1 to the earlier of date of death and/or last follow up, assessed up to 12 months
title
Overall Survival
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice